Quantcast

Latest BioLineRx Stories

2014-07-01 16:30:03

HAMPTON, N.J., July 1, 2014 /PRNewswire/ -- Bellerophon Therapeutics, LLC, a clinical stage biotherapeutics company, leveraging its proprietary drug-device technology platform for the development of innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases, today announced that Jonathan Peacock has been appointed Chairman and Chief Executive Officer. Peacock assumes the role of Chairman and Chief Executive Officer from...

2014-03-03 16:26:07

JERUSALEM, March 3, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs"), each representing ten (10) of its Ordinary Shares. All of the ADSs in the offering are to be sold by BioLineRx....

2014-02-24 08:27:34

JERUSALEM, Feb. 24, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20130730/630769) Dr. Panem has had an extensive and impressive career in the healthcare and life sciences industries in the U.S. Her experience...

2014-02-20 08:30:13

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use SummaryGBI Research has released its pharmaceutical research,...

2014-02-12 08:28:26

- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb. 12, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia. Results of the study were recently published in Molecular Cancer Therapeutics. (Logo:...

2014-02-03 08:27:02

JERUSALEM, Feb. 3, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the BIO CEO & Investor Conference on Monday, February 10, 2014 at 2:30 p.m. EST. The conference will be...

2014-01-23 08:30:32

- BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia - JERUSALEM, Jan. 23, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell...

2014-01-13 08:26:47

Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan. 13, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has filed the necessary regulatory submissions to commence a Phase 1 trial for BL-8040, a novel treatment for the mobilization of stem cells from the bone...

2014-01-08 08:27:23

- JHL Biotech to develop and commercialize BL-9020 in China and additional Southeast Asia countries - JERUSALEM and HSINCHU, Taiwan, Jan. 8, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, and JHL Biotech, a biopharmaceutical company that develops, manufactures, and commercializes biologic medicines, announced today that they have entered into...

2014-01-07 08:30:33

JERUSALEM, Jan. 7, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2014 Conference being held at the Parc 55 Wyndham Union Square Hotel in San Francisco, CA. (Logo:...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related